UNICREDIT BANK/CALL/AMGEN/500/0.1/17.12.25 | Real-time BOERSE MUENCHEN 03:10:28 29/05/2024 pm IST | ||
| 0.41 EUR | 0.00% |
|
| Current month | +105.00% | ||
| 1 month | +127.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 29/24/29 | 0.41 | 0.00% |
| 28/24/28 | 0.41 | -12.77% |
| 27/24/27 | 0.47 | 0.00% |
| 24/24/24 | 0.47 | -2.08% |
| 23/24/23 | 0.48 | -9.43% |
Real-time BOERSE MUENCHEN
Last update May 29, 2024 at 03:10 pm IST
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD2FAS |
| ISIN | DE000HD2FAS4 |
| Date issued | 05/02/2024 |
| Strike | 500 $ |
| Maturity | 17/12/2025 (568 Days) |
| Parity | 10 : 1 |
| Emission price | 0.68 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.67 € |
|---|---|
| Lowest since issue | 0.047 € |
| Spread | 0.12 € |
| Spread % | 26.09% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
300.2
USD
Average target price
316.3
USD
Spread / Average Target
+5.36%
- Stock Market
- Warrants
- Warrant
